News stories about Vermillion (NASDAQ:VRML) have been trending somewhat positive on Tuesday, according to Accern. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Vermillion earned a daily sentiment score of 0.08 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 42.9113646508136 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Separately, ValuEngine upgraded shares of Vermillion from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd.
Vermillion (NASDAQ VRML) traded up 2.10% on Tuesday, reaching $1.46. 44,598 shares of the company’s stock traded hands. Vermillion has a 52-week low of $0.76 and a 52-week high of $2.85. The stock’s 50 day moving average is $1.72 and its 200 day moving average is $1.81. The firm’s market cap is $81.89 million.
Vermillion (NASDAQ:VRML) last announced its earnings results on Thursday, May 18th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by $0.01. The company had revenue of $0.73 million for the quarter. Vermillion had a negative return on equity of 195.68% and a negative net margin of 443.29%. On average, equities research analysts predict that Vermillion will post ($0.16) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by Markets Daily and is the sole property of of Markets Daily. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.themarketsdaily.com/2017/08/08/vermillion-nasdaqvrml-receiving-somewhat-positive-media-coverage-analysis-finds.html.
Vermillion, Inc is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician’s clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery.
Receive News & Ratings for Vermillion Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion Inc. and related companies with MarketBeat.com's FREE daily email newsletter.